[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636122":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":49,"collaborators":20,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Tishreen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Botulinum Toxin Type A Group","EXPERIMENTAL","Participants with primary frontal hyperhidrosis will receive intradermal injections of botulinum toxin type A in the affected frontal area. Injection sites will be identified using Minor's iodine-starch test, followed by standardized grid-based mapping to ensure precise localization and uniform distribution of the toxin across the hyperhidrotic region.",[13],"Drug: Botulinum Toxin Type A",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Botulinum Toxin Type A","Botulinum toxin type A will be reconstituted with 5 mL of 0.9% sodium chloride solution to achieve a concentration of 20 units\u002FmL. Intradermal injections of 2 units per injection point will be administered using a 30-gauge insulin needle. The affected frontal area will be mapped using Minor's iodine-starch test and divided into a grid of approximately 2.25 cm² squares with 1 cm spacing between injection points. The total dose will range from 40 to 80 units depending on the extent of the affected area.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Zeinab Y Mohammad, MD","Latakia University","PRINCIPAL_INVESTIGATOR",[27,31],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","+963937109668","zeinab.y.mohammad@latakia-univ.edu.sy",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},"Mohamad A Ismaiel, MD, PhD","‪+963933471500‬","mohamad.ismaiel@latakia-univ.edu.sy",[36],{"facility":37,"status":38,"city":39,"state":20,"zip":20,"country":40,"countryCode":20,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Latakia University Hospital","RECRUITING","Latakia","Syria",{"type":42,"coordinates":43},"Point",[44,45],35.79088,35.53125,{"lat":45,"lon":44},[48],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},{"type":25,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Nabih Raslan, Dr","Principal Investigator","100636122","botulinum-toxin-type-a-for-frontal-hyperhidrosis-100636122",false,"NCT07561580","Botulinum Toxin Type A for Frontal Hyperhidrosis","Evaluation of the Efficacy of Botulinum Toxin Type A in the Treatment of Frontal Hyperhidrosis","Inclusion Criteria:\n\n* Patients aged between 18 and 40 years.\n\nClinically and objectively confirmed primary focal frontal hyperhidrosis, defined by sweat production \\>50 mg\u002Fmin and a Hyperhidrosis Disease Severity Scale (HDSS) score ≥3 (moderate to severe).\n\nInadequate response to topical antiperspirant therapy.\n\nNo prior treatment with Botulinum toxin type A within the last 6 months.\n\nNo use of any other hyperhidrosis treatment within the last 3 months.\n\nExclusion Criteria:\n\n* Secondary hyperhidrosis due to systemic conditions such as hyperthyroidism, diabetes mellitus, or neurological disorders.\n\nNeuromuscular disorders including myasthenia gravis or Lambert-Eaton syndrome. Active dermatological conditions or anatomical abnormalities in the frontal region (e.g., infections, inflammation, scars).\n\nKnown hypersensitivity to Botulinum toxin or any of its components. Pregnancy or breastfeeding. Use of medications that may interfere with Botulinum toxin activity (e.g., aminoglycosides) within one month prior to treatment.","ALL","18 Years","40 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67],"NA","Frontal hyperhidrosis is a form of primary focal hyperhidrosis that significantly impairs patients' quality of life due to excessive visible sweating in the forehead region. Conventional treatment options often show limited efficacy or may be associated with undesirable side effects.\n\nThis study aims to evaluate the efficacy and safety of intradermal injections of Botulinum Toxin Type A in patients with primary frontal hyperhidrosis. Clinical outcomes will be assessed using Minor's iodine-starch test, the Hyperhidrosis Disease Severity Scale (HDSS), and patient satisfaction scores. Participants will be followed up one month after treatment to evaluate therapeutic response and potential adverse effects.",[70],"Primary Frontal Hyperhidrosis",[72],"Frontal hyperhidrosis, Primary focal hyperhidrosis, Botulinum toxin type A, Intradermal injection, HDSS, Minor's starch iodine test.","2026-04-24",{"date":75,"type":76},"2026-05-01","ACTUAL",{"date":78,"type":76},"2025-11-20",{"date":80,"type":64},"2026-11-20",{"name":5,"class":6},1]